Skip to main content

Table 2 Registry-based algorithm based on treatment protocol name and details of each treatment protocol

From: Validation of a registry-derived risk algorithm based on treatment protocol as a proxy for disease risk in childhood acute lymphoblastic leukemia

Protocol Lineage Age (years) WBC (x109/L) Genetics Other Risk assignment
AALL02P2 T ≥10 (or)* ≥50 (or)    HR
AALL0031     t(9;22) or hypodiploidy or MLL with slow response (or) Induction failure (or) HR
AALL0232 B ≥10 (or) ≥50 (or)   Steroid pre treatment (or) HR
AALL0331 B 1-9 <50    SR
AALL0434 T >1     HR
AALL0622   >1   t(9;22)   HR
AALL0631   <1     HR
AALL0932 B 1-9 <50 No t(9;22), MLL, iAMP21, hypodiploidy   SR
CCG1991 B 1-9 <50    SR
POG9201 B 1-9 <50 Trisomy 4,10, DI>1.16 or t(12;21); No t(9;22), 1;19, MLL   SR
POG9407   <1     HR
POG9605 B 1-9 <50 No trisomy 4,10, DI>1.16, MLL, t(1;19), t(9;22)   SR
  B ≥10 <50 Trisomy 4,10 or DI>1.16; No MLL, t(1;19), t(9;22)   SR
  B >1 ≥50 Trisomy 4,10 or DI>1.16; No MLL, t(1;19), t(9;22)   SR
POG9904 B 1-9 <50 Trisomy 4,10, DI>1.16 or t(12;21); No MLL, t(1;19), t(9;22)   SR
POG9905      Neither 9904, 9906 nor AALL0031 SR
POG9906 B M>12; F>16 (or) >100 (or) MLL (or)   HR
  B Sliding scale of WBC criteria for M age 8–11 and F age 12-15   HR
Protocol C   <1 or >10 (or) >20 (or) t(9;22) or MLL (or) L2 morphology, mediastinal mass, or massive LN/HSM HR
  1. DI DNA index, F Female, HR High risk, HSM Hepatosplenomegaly, iAMP Intra-amplification, LN – Lymphadenopathy, M Male, SR Standard risk, WBC White blood cell.
  2. *(or) indicates factors for which any one was sufficient for inclusion into the protocol.